vibostolimab

Vibostolimab is a humanized monoclonal antibody that targets TIGIT (T cell immunoreceptor with Ig and ITIM domains), an immune checkpoint receptor expressed on T cells and natural killer (NK) cells. By blocking TIGIT, vibostolimab prevents its interaction with ligands such as CD112 and CD155, thereby restoring antitumor immune activity through activation of T lymphocytes. It was developed as an immunotherapy for various cancers, including non-small cell lung cancer (NSCLC), malignant melanoma, solid tumors, and renal cell carcinoma. Vibostolimab has been studied both as monotherapy and in combination with pembrolizumab (an anti–PD-1 antibody). Despite initial promise in early-phase trials, late-stage clinical development was discontinued after multiple studies failed to demonstrate significant improvement in overall survival or progression-free survival compared to standard therapies[2][3][6].